Cytosorbents Corporation(CTSO)Earnings, Financials & Key Ratios

CTSO•NASDAQ

$0.41

Price updated Jul 7, 2026

SectorHealthcare IndustryMedical Devices Sub-IndustryRenal, dialysis, and blood purification

AboutCytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Show more

Revenue$37M+4.1%
EBITDA-$13M+14.3%
Net Income-$8M+60.4%
EPS (Diluted)-0.13+65.8%
Gross Margin71.48%+2.2%
EBITDA Margin-34.02%+17.7%
Operating Margin-38.42%+16.9%
Net Margin-22.12%+62.0%
ROE-96.39%+20.0%

CTSO Price & Volume

Cytosorbents Corporation (CTSO) stock price & volume — 10-year historical chart

Loading chart...

Persistent Operating Losses Threaten Capital Base Stability

Investment Thesis • Updated 2026Q1

VerdictNegative: The company's precarious financial position is highlighted by a current ratio of 1.09 and a total equity base that has contracted to just $2.2M as of 2026Q1

Growth:Mixed

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Imminent liquidity and dilution

Key Thesis Takeaways

Cytosorbents faces a challenging outlook characterized by stagnant revenue growth and a persistent inability to achieve operational scale, as evidenced by operating margins frequently exceeding -40%.
The company's reliance on external financing to fund clinical development has led to a severe erosion of equity, which dropped from $23.3M in 2023Q4 to $2.2M in 2026Q1.
Investors should remain cautious regarding the firm's long-term viability given the narrowing liquidity buffer and the significant debt-to-equity ratio of 8.64.

Verdict Logic

indicating imminent liquidity and dilution risks.

CTSO Growth Metrics

Cytosorbents Corporation (CTSO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years24.76%

5 Years-1.24%

3 Years2.23%

TTM5.29%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM25.9%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM33.51%

Return on Capital

10 Years-70.53%

5 Years-45.99%

3 Years-50.66%

Last Year-39.54%

CTSO Recent Earnings

Cytosorbents Corporation (CTSO) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 6/12 qtrs (50%)●Beat Revenue 4/12 qtrs (33%)

Q2 2026Latest

May 13, 2026

Metric

Actual

Est

EPS

$0.08-33.3%

$0.06

Rev

$9M-5.7%

$9M

Q2 2026

Mar 25, 2026

Metric

Actual

Est

EPS

$0.09-80.0%

$0.05

Rev

$9M-5.6%

$10M

Q4 2025

Nov 13, 2025

Metric

Actual

Est

EPS

$0.04+33.3%

$0.06

Rev

$9M+2.9%

$9M

Q3 2025

Aug 7, 2025

Metric

Actual

Est

EPS

$0.05+28.6%

$0.07

Rev

$10M+4.3%

$9M

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 13, 2026	$0.08vs $0.06-33.3%	$9Mvs $9M-5.7%
Q2 2026	Mar 25, 2026	$0.09vs $0.05-80.0%	$9Mvs $10M-5.6%
Q4 2025	Nov 13, 2025	$0.04vs $0.06+33.3%	$9Mvs $9M+2.9%
Q3 2025	Aug 7, 2025	$0.05vs $0.07+28.6%	$10Mvs $9M+4.3%

Based on last 12 quarters of dataView full earnings history →

Latest CTSO News

Recent stock market news and headlines for Cytosorbents Corporation (CTSO)

GlobeNewsWire·Jun 18, 2026

CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026

PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the Life Sciences Forum hosted by VirtualInvestorConferences.com on Wednesday, June 24, 2026 and provide an overview and update on the Company. Following the presentation, Zacks Analyst Mr. Thomas Kerr will host a brief Q&A session with Dr. Chan and Mr. Peter Mariani, Chief Financial Officer.

Peers Comparison

Key metrics vs top competitors for Cytosorbents Corporation (CTSO)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
CTSOCytosorbents CorporationCurrent	$0.41	$25.54M	-3.13	4.12%	-22.12%	-96.39%	—
NVCRNovoCure Limited	$17.72	$2.02B	-14.52	8.28%	-25.66%	-50.82%	—
MASIMasimo Corporation	$179.95	$9.42B	-64.27	-27.1%	4.9%	9.08%	—
ICUIICU Medical, Inc.	$155.37	$3.88B	5284.69	-6.38%	2.15%	2.19%	—
LMATLeMaitre Vascular, Inc.	$105.70	$2.41B	41.94	13.53%	24.35%	16.19%	—
ATRCAtriCure, Inc.	$32.80	$1.66B	-136.67	14.88%	-0.83%	-0.95%	—

Compare CTSO vs Peers

Cytosorbents Corporation (CTSO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NVCR

Most directly comparable listed peer for CTSO.

Scale Benchmark

vs MDT

Larger-name benchmark to compare CTSO against a more recognizable public peer.

Peer Set

Compare Top 5

vs NVCR, MASI, ICUI, LMAT

CTSO SEC Filings & Documents

Cytosorbents Corporation (CTSO) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 13, 2026·SEC

Material company update

Apr 2, 2026·SEC

Material company update

Mar 25, 2026·SEC

10-K Annual Reports

FY 2026

Mar 30, 2026·SEC

FY 2025

Mar 31, 2025·SEC

10-Q Quarterly Reports

FY 2026

May 13, 2026·SEC

FY 2025

Nov 13, 2025·SEC

FY 2025

Aug 7, 2025·SEC

Get notified when CTSO posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

CTSO Frequently Asked Questions

Cytosorbents Corporation (CTSO) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Cytosorbents Corporation's revenue?

Cytosorbents Corporation (CTSO) reported $37.2M in revenue for fiscal year 2025. This represents a 371900% increase from $0.0M in 2005.

How fast is Cytosorbents Corporation growing?

Cytosorbents Corporation (CTSO) grew revenue by 4.1% over the past year. Growth has been modest.

Is CTSO profitable?

Cytosorbents Corporation (CTSO) reported a net loss of $11.8M for fiscal year 2025.

Dividend & Returns

What is CTSO's return on equity?

Cytosorbents Corporation (CTSO) has a return on equity (ROE) of -96.4%. Negative ROE indicates the company is unprofitable.

What is Cytosorbents Corporation's free cash flow?

Cytosorbents Corporation (CTSO) had negative free cash flow of $10.2M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in CTSO back in 2005?

Total return calculator · dividends reinvested · 21+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

May 13, 2026

$0.08vs $0.06-33.3%

$9Mvs $9M-5.7%

Q2 2026

Mar 25, 2026

$0.09vs $0.05-80.0%

$9Mvs $10M-5.6%

Q4 2025

Nov 13, 2025

$0.04vs $0.06+33.3%

$9Mvs $9M+2.9%

Q3 2025

Aug 7, 2025

$0.05vs $0.07+28.6%

$10Mvs $9M+4.3%

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

CTSOCytosorbents CorporationCurrent

$0.41

$25.54M

-3.13

4.12%

-22.12%

-96.39%

—

NVCRNovoCure Limited

$17.72

$2.02B

-14.52

8.28%

-25.66%

-50.82%

—

MASIMasimo Corporation

$179.95

$9.42B

-64.27

-27.1%

4.9%

9.08%

—

ICUIICU Medical, Inc.

$155.37

$3.88B

5284.69

-6.38%

2.15%

2.19%

—

LMATLeMaitre Vascular, Inc.

$105.70

$2.41B

41.94

13.53%

24.35%

16.19%

—

ATRCAtriCure, Inc.

$32.80

$1.66B

-136.67

14.88%

-0.83%

-0.95%

—